Funding

Apart from support through the University for Veterinary Medicine, the Moriggl lab receives currently mainly funding from the Austrian Science Fund (FWF), the Ludwig Boltzmann Gesellschaft (LBG GmbH), the Austrian Research Promotion Agency (FFG), the National Institute of Health (NIH) and generous support by a private foundation from Liechtenstein.

Two special research programmes (SFB) of the Austrian Science Fund (to website Austrian Science Fund 1):

 

SFB-F28 JAK-STAT Signalling

Logo Jak-Stat
Logo Jak-Stat

SFB F28 ran from 2006 to 2016 and is now successfully completed. It was headed by Prof. Mathias Müller from the Vetmeduni Vienna with deputy speaker Prof. Thomas Decker from the Max Perutz Laboratories. The final report  2is publicly available on the project website.

The particular strength of the research was to apply the fundamental knowledge about Jak-Stat mechanisms in cellular processes to the next level of complexity. The strength of SFB-JakStat was that the contributing research teams had a pathway-centric view on molecular mechanistics, disease causalities and therapeutic interventions. The national and international renowned collaborative network that developed over the past decade will be further fostered by the long-term members of the consortium. The regular meetings with external speakers and progress reports of the JAK-STAT centric groups will be perpetuated. Most importantly, the core members of the consortium have submitted a follow-up SFB concept termed “Monarchie and Hierarchies in Shaping Chromatin Landscapes”, which will be reviewed in June 2016 for possible funding.

Weblink to SFB-F28 3

To top

 
Overview Jak-Stat Signalling
Overview Jak-Stat Signalling 4
 

SFB-F47: Myeloproliferative Neoplasias

Logo SFB-F47
Logo SFB-F47

SFB F47 can run from 2013 to 2021 and it is now undergoing interims evaluation in 2016. It is headed by Prof. Peter Valent from the Medical University Vienna with deputy speaker Prof. Richard Moriggl from the Vetmeduni Vienna and it consists of five different institutions with 10 research groups participating.

The general aim of SFB F47 is to identify and characterize novel clinically relevant markers and targets in patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) and other myeloproliferative neoplasms (MPN) such as JAK2 V617F+ MPN, CALR+, thereby providing novel tools and strategies for the development of improved diagnostic and therapeutic approaches. The ultimate aim of the SFB is to improve targeted therapies in CML and other MPN by developing novel LSC-eradicating treatment concepts. The RM group focuses on targeting STAT5.

Weblink to SFB F47 5

To top